Researchers also associate ending GLP-1 therapy before pregnancy with a few risks.* Women who stopped taking a GLP-1 RA before or during early pregnancy had roughly 1.3x the risk of preterm birth, gestational diabetes, and high blood pressure conditions during pregnancy, compared to similar women who had not taken a GLP-1 RA
You can read the full article at Recent research suggests a possible connection between Attention-Deficit/Hyperactivity Disorder (ADHD) and obesity
The signaling pathway of GLP-1R is of great significance in modulating the immune reaction of these T cells, which is closely linked to their activation, apoptosis, metabolism, and migratory capacity [16]
Rapid weight loss often leads to significant lean mass loss, which can negatively affect metabolism, bone density, and long term strength
Emerging research is indicating that these meds may also create dysbiosis
The research progressed rapidly with studies performed in primates and healthy humans
